Tern Plc invests $280,000 in Device Authority convertible loan notes

TERN

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things (IoT) technology businesses, has announced that it has invested US$280,000 (approximately £209,000) in new unsecured convertible loan notes issued by Device Authority Limited.  The investment in the Device Authority CLNs will be funded from the proceeds of the Company’s recent Open Offer.

The CLNs carry an interest rate of 8 per cent. per annum and the CLNs’ principal amount and accrued interest are convertible on either a change of control of Device Authority, or a fundraising of at least US$5 million (a “Qualifying Fundraise”) undertaken by Device Authority, or, if neither have occurred on 30 June 2027.  On a change of control, the CLNs are convertible at a three times multiple to their face value and the value of accrued interest.  On a Qualifying Fundraise the CLNs are convertible at a 25 per cent discount to the Qualifying Fundraise price.  If neither a change of control nor a Qualifying Fundraise has taken place, the CLNs will mature on 30 June 2027.

As at 30 June 2025, the date of Tern’s last published book valuation, Tern’s holding in Device Authority had a total unaudited book value of £4.0 million. Following the issue of the CLN, Tern’s equity holding in Device Authority will be unchanged and Tern will continue to hold approximately 25.3% of Device Authority’s equity (before any dilution on exercise of share options), although now with a CLN holding of approximately £0.21 million.

As part of the same overall funding round, Device Authority is in the process of raising up to US$1.6 million of funding from existing investors through the issue of CLNs on the same terms.

Jane McCracken, Interim Non-Executive Chair of Tern, said: “We are pleased to be able to provide this further funding to Device Authority, which is part of a larger fundraise by the business to ensure they have sufficient working capital to service significant contracts expected in the near term. We remain very excited by the potential of Device Authority and our other portfolio companies, and are focused on realising value from them as soon as is appropriate.”

Further information on Device Authority

Device Authority is a global leader in Identity and Access Management (IAM) for the IoT; focused on the automotive, medical device (IoMT) and industrial (IIoT) sectors. Device Authority’s KeyScaler™ platform provides zero touch provisioning and complete automated lifecycle management for securing IoT devices and data at scale, with frictionless deployment across device provisioning, authentication, credential management, policy based end-to-end data security/encryption and secure OTA (over the air) and HSM (hardware security module) updates.

Based on Device Authority’s latest statutory accounts for the year ended 31 December 2025, as at that date it had net assets of approximately £11,609,000 and incurred a loss for the year of approximately £1,750,000. Given the historic and statutory nature of these figures, Tern does not consider this to be representative of the current business, trading performance and prospects of Device Authority.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Device Authority targets secure digital infrastructure for smart ports

Device Authority's Smart, Green Port Blueprint shows how secure device management can support the wider rollout of connected infrastructure across modern ports.

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Search